Muscle wasting in chronic obstructive pulmonary disease (COPD): the role of resistance training and protein supplementation

Molecular approaches to reversing skeletal muscle wasting in chronic obstructive pulmonary disease (COPD): the role of resistance training and protein supplementation - a double-blind randomised placebo-controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN22764439

Enrollment

120

Registered

2009-12-09

Start date

2007-02-14

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD) Respiratory Other chronic obstructive pulmonary disease

Interventions

1. Resistance training: The training programme will last 8 weeks and comprise three supervised half-hour lower limb resistance training sessions per week. Training will take place on an isokinetic dyn

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: For both COPD subjects and healthy control subjects: 1. Both males and females, aged between 50-85 years COPD subjects: 1. Moderate-severe airflow obstruction (Forced expiratory volume in one second [FEV1] 80% predicted) 2. Able to carry out lower-limb resistance training

Exclusion criteria

Exclusion criteria: COPD subjects: 1. Long-term oral corticosteriods 2. Anticoagulant therapy or disorders 3. long term oxygen therapy (LTOT) 4. Diabetes 5. Co-morbid conditions preventing exercise training 6. Subects who have completed pulmonary rehabilitation in the previous 12-months Healthy age-matched controls: Same as for COPD subjects, also those who meet the criteria for fat-free mass depletion are excluded.

Design outcomes

Primary

Measure	Time frame
Muscle gene and protein expression (vastus lateralis needle biopsy samples) at baseline, 24 hours, 4 weeks and 8 weeks.	—

Secondary

Measure	Time frame
1. Muscle strength (isometric and isokinetic quadriceps strength) at baseline, 4 weeks, 8 weeks and 6 months 2. Total body and quadriceps fat-free (muscle) mass (dual energy X-ray absorptiometry [DEXA]) at baseline, 4 weeks and 8 weeks 3. Circulating inflammatory cytokines (blood tests) at baseline, 24 hours, 4 weeks and 8 weeks 4. Whole-body exercise performance (incremental cycle ergometry test) at baseline and 8 weeks 5. Physical activity (questionnaire and activity monitor) at baseline and 8 weeks 6. Lung function and capillary blood gas tensions at baseline	—

Measure

Time frame

1. Muscle strength (isometric and isokinetic quadriceps strength) at baseline, 4 weeks, 8 weeks and 6 months 2. Total body and quadriceps fat-free (muscle) mass (dual energy X-ray absorptiometry [DEXA]) at baseline, 4 weeks and 8 weeks 3. Circulating inflammatory cytokines (blood tests) at baseline, 24 hours, 4 weeks and 8 weeks 4. Whole-body exercise performance (incremental cycle ergometry test) at baseline and 8 weeks 5. Physical activity (questionnaire and activity monitor) at baseline and 8 weeks 6. Lung function and capillary blood gas tensions at baseline

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 25, 2026